Latest Update: As of September 12, 2026, the Paraquat MDL (No. 3004) remains in the settlement-administration phase before Judge Nancy Rosenstengel in the Southern District of Illinois, with no global settlement value finalized. The most recent confirmed case count, reported August 3, 2026, put the MDL at 6,665 pending cases out of 8,484 total filed. Separately, on August 10, 2026, the California Department of Pesticide Regulation announced that all paraquat manufacturers had voluntarily canceled their state product registrations, beginning a phase-out of the herbicide in California. Syngenta had previously said it would halt global paraquat production by the end of June 2026 while continuing to sell existing supply through the end of the year.
Last updated: September 2026
The paraquat lawsuit is one of the largest active mass torts in the United States right now, and 2026 is shaping up to be a defining year for tens of thousands of victims. Thousands of people who worked on farms, lived near agricultural fields, or were otherwise exposed to the weed killer paraquat have developed Parkinson’s disease and are now seeking compensation from the companies that made it.
This article covers everything you need to know about where the case stands in 2026. You’ll find the latest settlement news, who qualifies to file, how much money claimants might receive, key court deadlines, and what the MDL process means for your case.
Over 20,000 individual lawsuits have been filed in federal court. The pressure on defendants Syngenta and Chevron is building. Here’s what’s actually happening.
Paraquat Lawsuit Update 2026: Where Does the Case Stand Right Now?
The paraquat lawsuit update for 2026 shows the litigation is at a critical turning point, with global settlement talks gaining serious momentum while federal court proceedings continue in the background.
As of early 2026, the consolidated federal litigation known as MDL No. 3004 remains active in the U.S. District Court for the Southern District of Illinois. Judge Nancy Rosenstengel continues to oversee the proceedings. The docket now includes over 20,000 individual plaintiff cases, making this one of the most significant mass tort actions in recent memory.
Syngenta and Chevron, the two primary defendants, have resisted early settlement offers in the past. But legal analysts following the case closely say the sheer volume of plaintiffs and the strength of scientific evidence linking paraquat to Parkinson’s disease has shifted the pressure significantly toward a resolution.
2026 Quick Status Snapshot:
| Category | Current Status |
|---|---|
| MDL Case Number | MDL No. 3004 |
| Court | Southern District of Illinois |
| Presiding Judge | Judge Nancy Rosenstengel |
| Total Filed Cases (est.) | 20,000+ |
| Primary Defendants | Syngenta AG, Chevron Phillips Chemical |
| Settlement Status | Active negotiations as of 2026 |
| Expected Resolution | 2026 to 2027 window |
The litigation has moved slowly by mass tort standards. But the pace is accelerating.
Latest on Paraquat Lawsuit: What Happened in the Past 12 Months
The latest on the paraquat lawsuit includes significant shifts in courtroom strategy and renewed pressure on both defendants to reach a broader settlement.
In 2024 and into 2025, several bellwether trials were scheduled to test how juries would respond to the science connecting paraquat to Parkinson’s disease. Syngenta successfully had several of those early test cases dismissed or removed from trial schedules, which frustrated plaintiffs’ attorneys but did not shut down the broader litigation.
By late 2025 and into 2026, plaintiffs’ legal teams regrouped. New expert witness testimony was submitted, and additional scientific studies emerged strengthening the biological case against paraquat. The National Institutes of Health and several independent research institutions published findings consistent with what plaintiffs have argued for years.
Key Events Over the Past 12 Months:
- Renewed expert witness disclosures filed in late 2025
- Additional epidemiological studies entered into the court record
- Settlement discussions between lead counsel and defense teams escalated
- Judge Rosenstengel issued several case management orders pushing timelines forward
- New plaintiffs continued filing at a rate of hundreds per month through early 2026
The case is not stalled. It’s moving. Slowly, but deliberately.
Paraquat Lawsuit Settlement News: Are Defendants Ready to Pay?
Paraquat lawsuit settlement news in 2026 indicates that Syngenta and Chevron are under increasing legal and financial pressure to negotiate a global resolution rather than face thousands of individual trials.
No official global settlement has been announced as of the time of this writing. But that doesn’t mean nothing is happening. Settlement talks in major mass torts typically happen behind closed doors, well before any public announcement. The pattern here mirrors what happened with the Roundup glyphosate litigation before Bayer announced its $10 billion settlement.
Plaintiffs’ attorneys have described the 2026 negotiations as the most productive the case has seen. Both sides have retained settlement mediators. That’s a significant signal.
What Settlement News Tells Us:
| Signal | What It Means |
|---|---|
| Mediators retained by both sides | Serious talks underway |
| No bellwether jury verdicts yet | Defendants still testing strategy |
| 20,000+ plaintiffs | Enormous financial exposure for defendants |
| Strong scientific evidence | Plaintiffs hold strong negotiating position |
| Similar cases settled globally | International pressure on Syngenta |
The most likely outcome in 2026 is a structured settlement fund announcement, similar to what was done in the 3M earplug or Roundup cases.
Key Takeaway: The paraquat lawsuit is heading toward a global settlement rather than mass individual trials, and 2026 is the year that decision is likely to crystallize.
Paraquat Settlement Amount 2026: What Are the Numbers Looking Like?
The paraquat settlement amount in 2026 has not been officially set, but legal analysts and plaintiffs’ attorneys estimate the total fund could reach between $3 billion and $9 billion across all claimants.
Those numbers sound large, and they are. But divide them by 20,000-plus claimants and the picture gets more specific. The per-person payout depends heavily on injury severity, length of exposure, and how well an individual claim is documented.
Settlements in mass torts like this typically operate on a tiered compensation structure. Plaintiffs with the most severe Parkinson’s diagnoses, the clearest exposure history, and the youngest age of onset tend to receive the highest awards.
Estimated Settlement Tier Structure:
| Tier | Qualifying Criteria | Estimated Range |
|---|---|---|
| Tier 1 (Highest) | Severe Parkinson’s, documented heavy exposure, young onset | $500,000 to $2,000,000+ |
| Tier 2 (Moderate) | Confirmed Parkinson’s diagnosis, moderate exposure history | $150,000 to $499,000 |
| Tier 3 (Lower) | Parkinson’s diagnosis, limited exposure documentation | $50,000 to $149,000 |
| Tier 4 (Base) | Exposure confirmed but early or partial Parkinson’s symptoms | $10,000 to $49,000 |
These ranges are based on patterns from comparable mass tort settlements. Actual amounts will depend on how the final settlement is structured.
Attorney fees in contingency cases typically run 33% to 40% of the gross settlement amount, which factors into what a plaintiff actually takes home.
Paraquat Lawsuit Payout Per Person: What Will Individual Claimants Receive?
The paraquat lawsuit payout per person is expected to vary widely, with estimates ranging from tens of thousands of dollars for lower-tier claims to well over one million dollars for the most severely affected plaintiffs.
Think of it like an insurance payout after a car accident. The more severe the damage and the clearer the liability, the higher the check. The same principle applies here. Parkinson’s disease is devastating. When it’s caused by someone else’s negligence, the law attempts to put a dollar amount on that harm.
Factors that drive individual payout amounts higher include:
- A documented Parkinson’s disease diagnosis from a licensed neurologist
- Provable direct exposure to paraquat (employment records, farm records, property records)
- Extended duration of exposure (years, not months)
- Early age of Parkinson’s onset (diagnosis before age 60)
- Severe disease progression requiring full-time care
- Medical expenses incurred because of the disease
- Loss of income or earning capacity
- Pain and suffering documentation
Plaintiffs who can check most of those boxes are in the strongest position.
Key Takeaway: Individual payouts depend on severity of Parkinson’s disease and strength of exposure documentation. Those with the most complete records tend to receive the most.
Paraquat Lawsuit Who Qualifies: Do You Have a Valid Claim?
The paraquat lawsuit qualifies anyone who was directly exposed to paraquat herbicide and subsequently developed Parkinson’s disease, with no prior Parkinson’s diagnosis before the exposure.
That’s the core requirement. But there’s more nuance underneath it.
Qualifying claimants fall into specific categories. This isn’t limited to just farmers. Anyone who lived near treated fields, worked at facilities that stored or mixed paraquat, or applied the herbicide professionally may have a valid claim.
Who Typically Qualifies:
- Farmers and agricultural workers who applied paraquat directly
- Farm laborers who worked fields treated with paraquat
- People who lived within close proximity to fields treated with paraquat
- Groundskeepers, landscapers, or turf managers who used paraquat products
- Workers at agricultural supply facilities handling the chemical
- Family members of applicators who brought contamination home on clothing
Who May Not Qualify:
- People with Parkinson’s disease but no documented exposure to paraquat
- People with exposure but no Parkinson’s diagnosis or related symptoms
- People whose diagnosis preceded any possible paraquat exposure period
The exposure period most commonly cited in lawsuits runs from the 1960s through the present, given how long paraquat has been commercially available in the U.S.
Paraquat Lawsuit Eligibility Requirements: The Specific Criteria You Need to Meet
The paraquat lawsuit eligibility requirements involve four core elements: confirmed Parkinson’s disease diagnosis, documented exposure to paraquat, a reasonable timeline connecting exposure to diagnosis, and no disqualifying prior medical history.
This is where a lot of people get tripped up. The eligibility bar is real, and not every Parkinson’s patient automatically has a paraquat claim. The key is connecting the exposure to the disease.
Full Eligibility Criteria Breakdown:
| Requirement | Details |
|---|---|
| Parkinson’s Disease Diagnosis | Must be confirmed by a licensed neurologist |
| Paraquat Exposure | Direct contact through work, residence, or proximity to treated fields |
| Exposure Timeline | Typically exposure before Parkinson’s diagnosis by at least several years |
| No Prior Diagnosis | Parkinson’s symptoms must not predate the exposure history |
| U.S. Jurisdiction | Claim must be filed in U.S. federal court system |
| Statute of Limitations | Must file within your state’s limitation period (typically 2 to 3 years from diagnosis date) |
Supporting documentation strengthens any claim significantly. Employment records from farms, pesticide application licenses, tax records showing farm income, or medical records documenting proximity to treated land all help.
The stronger your paper trail, the stronger your position in a tiered settlement.
Paraquat Lawsuit Filing Deadline: When Is the Cutoff?
The paraquat lawsuit filing deadline varies by state, but most jurisdictions give claimants two to three years from the date they were diagnosed with Parkinson’s disease to file a lawsuit.
Missing this deadline means losing your right to compensation permanently. There are very few exceptions.
Statutes of limitations in personal injury and mass tort cases are strict. Courts rarely allow late filings, even when a plaintiff didn’t know about the paraquat connection until much later. Some states apply the “discovery rule,” which starts the clock when you discovered or reasonably should have discovered the link between your illness and the chemical exposure.
Filing Deadline Overview by Approach:
| Rule Type | How It Works | States That Commonly Apply It |
|---|---|---|
| Standard Statute of Limitations | Clock starts at diagnosis date | Most states |
| Discovery Rule | Clock starts when you learned of the paraquat link | California, New York, others |
| Tolling for Minors | Clock paused until plaintiff turns 18 | Most states |
| Fraudulent Concealment | Clock paused if manufacturer actively hid risks | Varies by state |
The bottom line: If you or a family member has Parkinson’s disease and any history of paraquat exposure, do not wait. The clock is already running.
Key Takeaway: Filing deadlines in paraquat cases are real and unforgiving. The discovery rule may help in some states, but acting sooner is always better than waiting.
How to File a Paraquat Claim: A Step-by-Step Overview
Filing a paraquat claim involves gathering your medical records, documenting your exposure history, contacting a mass tort attorney, and joining the existing MDL in the Southern District of Illinois.
You don’t need to hire a lawyer to file, but virtually every successful paraquat plaintiff works with one. Mass tort attorneys in this space typically work on contingency, meaning no upfront costs.
Step-by-Step Filing Process:
- Get your medical records together. You need your Parkinson’s disease diagnosis confirmed in writing by a neurologist. Hospital records, doctor’s notes, and prescription histories all count.
- Document your exposure. Pull together employment records, old W-2s, farm tax records, land records showing proximity to treated fields, or pesticide application records.
- Contact a mass tort law firm. Look for firms with specific paraquat litigation experience. They’ll conduct a free case evaluation.
- Sign a contingency agreement. Most firms take 33% to 40% of your settlement if you win. You pay nothing upfront.
- Your attorney files your case. It’s either added to the existing MDL or filed in state court, depending on your situation.
- Wait for MDL proceedings. Your case joins thousands of others. You don’t have to appear in court. Your attorney handles everything.
The process isn’t fast, but it’s not complicated if you have the right legal team.
Paraquat MDL Update 2026: What’s Happening in Federal Court
The paraquat MDL update for 2026 shows the litigation consolidated in the Southern District of Illinois is moving through pre-trial phases, with both sides preparing for a potential global settlement or resumed bellwether trials.
MDL stands for Multi-District Litigation. It’s a federal mechanism that consolidates thousands of similar lawsuits into one court to avoid duplicating pretrial work. Think of it like everyone in the same building using one shared conference room for depositions and discovery, even if each case eventually gets its own hearing.
MDL No. 3004 has been active since 2021. Judge Rosenstengel has managed it methodically. The 2026 phase involves case-specific discovery, meaning defendants and plaintiffs exchange individual medical records, exposure documents, and expert opinions for a set of “discovery pool” cases selected to represent the broader plaintiff population.
MDL 2026 Activity Summary:
| Activity | Status |
|---|---|
| Case-specific discovery | Active in 2026 |
| Expert witness depositions | Ongoing |
| Daubert hearings (expert admissibility) | Expected mid-2026 |
| Bellwether trial selections | Under negotiation |
| Global settlement talks | Active behind closed doors |
| Total cases in MDL | 20,000+ |
Daubert hearings, which determine whether scientific expert testimony is admissible at trial, are a critical 2026 milestone. The outcome of those hearings will directly influence settlement amounts and trial strategy.
Paraquat Bellwether Trial Update: What Happened to the Test Cases
The paraquat bellwether trial update reveals that early test trials scheduled for 2023 and 2024 were delayed or dismissed, but new bellwether cases are being prepared for 2026 and could determine the direction of the entire litigation.
Bellwether trials work like weather vanes. Pick a handful of representative cases, take them to trial, and see how juries respond. If juries award big verdicts, defendants rush to settle. If juries side with defendants, settlement demands drop. The stakes in these test cases are enormous for both sides.
Syngenta argued successfully in earlier rounds that certain expert witnesses should not be allowed to testify, which knocked out some bellwether trials before they could start. Plaintiffs’ teams have since refined their expert witness presentations and filed new and revised opinions entering 2026.
Bellwether Trial Timeline:
| Year | Event |
|---|---|
| 2021 | MDL consolidated in Southern District of Illinois |
| 2022 | Initial bellwether selections made |
| 2023 | Syngenta filed Daubert challenges to expert witnesses |
| 2024 | Several bellwether trials delayed or dismissed |
| 2025 | Plaintiffs filed revised expert witness disclosures |
| 2026 | New bellwether trials expected; Daubert hearings scheduled |
The outcome of 2026 bellwether proceedings will almost certainly trigger the global settlement announcement this litigation has been building toward.
Key Takeaway: Bellwether trials in 2026 are the most important short-term development in the paraquat MDL. Their outcome will drive the final settlement number for all plaintiffs.
Paraquat Parkinson’s Disease Lawsuit: Understanding the Health Claims
The paraquat Parkinson’s disease lawsuit is built on scientific evidence that paraquat exposure causes damage to dopamine-producing brain cells, which is the core biological mechanism of Parkinson’s disease.
This isn’t a speculative theory. It’s a connection that has been studied in peer-reviewed research for over three decades.
Paraquat is a powerful oxidant. When it enters the human body through inhalation, skin contact, or ingestion, it generates toxic molecules called reactive oxygen species. These molecules attack and destroy dopaminergic neurons in a region of the brain called the substantia nigra. Dopamine production drops. Motor function deteriorates. Parkinson’s disease develops.
Laboratory studies conducted on animal models going back to the 1990s consistently reproduced Parkinson’s-like neurological damage using paraquat. Epidemiological studies of farm workers in California, Europe, and Asia showed significantly higher rates of Parkinson’s disease in populations with regular paraquat exposure.
The National Institutes of Health, the Michael J. Fox Foundation, and several academic medical centers have all published research supporting this connection. That’s not fringe science. That’s mainstream neurology.
Why This Matters for Your Claim:
- The science gives plaintiffs a credible, peer-reviewed foundation
- Defendants cannot argue the link is completely unknown or unproven
- Expert witnesses can testify on causation with high credibility
- Juries with this evidence tend to find in favor of plaintiffs
Paraquat Syngenta Lawsuit: What Role Does Syngenta Play
The paraquat Syngenta lawsuit names Syngenta AG, a Swiss-based agrochemical company and the primary manufacturer of paraquat under the brand name Gramoxone, as the principal defendant responsible for knowingly selling a dangerous product.
Syngenta is the company plaintiffs blame most directly. They manufactured and sold Gramoxone, the most widely used paraquat product in the United States, for decades. Internal company documents surfaced during discovery suggest Syngenta was aware of research connecting paraquat to neurological damage well before the public was informed.
That’s the core of the negligence claim. It’s not just that the product was dangerous. It’s that Syngenta allegedly knew it was dangerous and kept selling it anyway without adequate warnings.
Syngenta’s Position in the Litigation:
| Element | Details |
|---|---|
| Company | Syngenta AG (headquartered in Basel, Switzerland) |
| Parent Company | ChemChina (acquired Syngenta in 2017) |
| Primary Product | Gramoxone (paraquat-based herbicide) |
| Legal Theory Against Them | Failure to warn, negligent design, product liability |
| Current Stance | Contesting liability; Daubert challenges filed |
| Financial Exposure | Potentially billions in settlement or verdicts |
Syngenta’s acquisition by the Chinese state-owned company ChemChina in 2017 added an international dimension to the litigation and raised questions about enforcement of any eventual judgment.
Paraquat Chevron Lawsuit: Chevron’s Role in the Litigation
The paraquat Chevron lawsuit targets Chevron Phillips Chemical Company, a former manufacturer of paraquat in the United States, for its role in producing and distributing the herbicide during decades when it was sold commercially.
Chevron is the secondary defendant and plays a different role than Syngenta. Where Syngenta is the ongoing manufacturer, Chevron’s liability stems primarily from its historical manufacturing activity before the company exited the paraquat market.
Plaintiffs argue Chevron had the same obligation to warn consumers and workers about paraquat’s risks. Failing to do so while profiting from the product’s sale makes them jointly liable for the resulting harm.
Chevron’s Position in the Litigation:
| Element | Details |
|---|---|
| Company | Chevron Phillips Chemical Company |
| Role | Former U.S. manufacturer and distributor of paraquat |
| Legal Theory | Failure to warn, product liability |
| Current Stance | Contesting liability alongside Syngenta |
| Key Argument | Historical activity; limited modern exposure |
Some individual plaintiffs may have stronger claims against Chevron if their exposure occurred during the period when Chevron was the active manufacturer in their region. This is why exposure dates and documentation matter enormously.
Paraquat Herbicide Dangers: Why This Chemical Is So Controversial
Paraquat herbicide is one of the most toxic agricultural chemicals ever commercially produced, so dangerous that a single sip of concentrated solution can kill a person, and it has been banned outright in 32 countries.
Despite its extreme toxicity, the U.S. Environmental Protection Agency continues to allow paraquat’s use in the United States, though only by certified applicators. This stands in sharp contrast to the European Union, the UK, China, and dozens of other nations that banned it years ago.
The controversy has intensified as the lawsuits multiplied. Consumer and environmental advocacy groups have pushed the EPA repeatedly to issue a full ban. The EPA conducted a registration review of paraquat and in 2021 concluded the chemical posed no unreasonable risks when used according to label directions. Plaintiffs and scientific critics called that conclusion deeply flawed.
Global Paraquat Regulatory Status:
| Region/Country | Regulatory Status |
|---|---|
| United States | Permitted (restricted use only, certified applicators) |
| European Union | Banned since 2007 |
| United Kingdom | Banned |
| China | Banned (in 2020, despite Syngenta ownership by ChemChina) |
| Brazil | Banned |
| 32+ other nations | Banned |
The fact that the U.S. still allows paraquat while most of the developed world bans it is one of the most powerful arguments plaintiffs bring to court.
Key Takeaway: Paraquat is banned in most of the world but still legal in the U.S., and that regulatory double standard is central to plaintiffs’ argument that Syngenta and Chevron knew about the dangers long before they disclosed them.
Paraquat Lawsuit Timeline: From First Lawsuits to 2026 Resolution
The paraquat lawsuit timeline stretches from early scientific warnings in the 1980s all the way through the active 2026 MDL proceedings and expected settlement announcements.
Understanding how this case developed over decades helps explain why it’s so large today. The harm didn’t happen overnight. It accumulated over generations of agricultural workers and rural communities who trusted that a government-approved product was safe.
Full Paraquat Lawsuit Timeline:
| Year | Event |
|---|---|
| 1964 | Paraquat commercially introduced in the United States |
| 1980s | First peer-reviewed studies link paraquat to neurological damage in animals |
| 1990s | Epidemiological studies show elevated Parkinson’s rates in agricultural workers |
| 2011 | NIH-funded Parkinson’s Genes and Environment study confirms paraquat-Parkinson’s link in humans |
| 2017 | First major paraquat lawsuits filed in state courts |
| 2021 | Federal MDL consolidated in Southern District of Illinois as MDL No. 3004 |
| 2021 | EPA issues registration review; declines to ban paraquat |
| 2022 | Bellwether selection process begins |
| 2023 | Syngenta files Daubert challenges to plaintiff expert witnesses |
| 2024 | Several bellwether trials delayed or dismissed; plaintiffs regroup |
| 2025 | Revised expert witness disclosures filed; settlement talks escalate |
| 2026 | Daubert hearings expected; new bellwether trials possible; global settlement announcement anticipated |
This is a slow-moving case by design. Mass torts of this scale rarely resolve in less than a decade. The Roundup litigation started in 2015 and Bayer didn’t announce its multi-billion settlement until 2020. The paraquat case is following a similar arc.
Frequently Asked Questions
What is the current status of the paraquat lawsuit in 2026?
The paraquat lawsuit is in active MDL proceedings in the Southern District of Illinois with over 20,000 cases filed.
Settlement negotiations between plaintiffs and defendants Syngenta and Chevron are ongoing and are considered the most advanced they have been since the litigation began.
Daubert hearings on expert witness testimony are expected in 2026 and will be a key milestone in determining how the case resolves.
How much money can I get from the paraquat lawsuit?
Paraquat lawsuit settlements are expected to range from $10,000 to over $1,000,000 per claimant depending on injury severity and documentation.
Plaintiffs with severe Parkinson’s disease, confirmed exposure history, and strong medical records tend to qualify for the highest compensation tiers.
No official settlement fund has been announced yet as of 2026.
Who qualifies for the paraquat lawsuit?
Anyone diagnosed with Parkinson’s disease who has a documented history of paraquat exposure may qualify to file a claim.
This includes farmers, farm workers, people who lived near treated fields, and anyone who worked with or around Gramoxone or other paraquat products.
A neurologist-confirmed Parkinson’s diagnosis and evidence of exposure are the two core requirements.
Is there still time to file a paraquat claim in 2026?
Most states give claimants two to three years from their Parkinson’s diagnosis date to file a lawsuit, so many people diagnosed in 2024 or later still have time.
Some states apply the discovery rule, which starts the clock when you learned about the paraquat connection, which may extend your window further.
Acting now rather than waiting is strongly advisable because statutes of limitations are strict and courts rarely grant exceptions.
What is Syngenta’s role in the paraquat lawsuit?
Syngenta AG is the primary defendant and the manufacturer of Gramoxone, the most widely sold paraquat-based herbicide in the United States.
Plaintiffs allege Syngenta knew about research connecting paraquat to Parkinson’s disease and failed to adequately warn consumers and agricultural workers.
Syngenta is contesting liability and has used Daubert motions to challenge expert witness testimony in the MDL.
Where Things Stand and What to Do Next
The paraquat lawsuit is real, it’s massive, and 2026 is the year it could finally reach the resolution that tens of thousands of sick victims have been waiting years for. The science is strong. The case count is enormous. The pressure on defendants is mounting.
If you or someone in your family developed Parkinson’s disease after working with or around paraquat, the time to act is now. Gather your medical records and any documentation of exposure you can find.
The statute of limitations won’t wait. Neither should you.
